Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 10 years of Change in Account Payables data on file, last reported at -$12.0 million in Q2 2026.

• Quarterly Change in Account Payables fell 273.15% year-over-year to -$12.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.4 million (up 111.06% YoY) and the FY2025 annual result came in at $142000.0, up 102.25% from the prior year.
• Change in Account Payables fell to -$12.0 million in Q2 2026, from $22.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $22.3 million in Q1 2026 to a low of -$12.0 million in Q2 2026.
• A 5-year average of $582277.8 and a median of -$340500.0 in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables slumped 529.57% — and 2026, when it jumped 35812.9%.
• Tracing KNSA's Change in Account Payables over 5 years: stood at $6.4 million in 2022, then increased by 12.5% to $7.2 million in 2023, then sank by 186.87% to -$6.3 million in 2024, then jumped by 34.4% to -$4.1 million in 2025, then tumbled by 191.1% to -$12.0 million in 2026.
• The last three Change in Account Payables figures came in at -$12.0 million (Q2 2026), $22.3 million (Q1 2026), and -$4.1 million (Q4 2025), per Business Quant data.